This is a $5,240,000.00 firm fixed price definitive contract awarded by the National Heart, Lung, and Blood Institute (NHLBI), a civilian agency, to Lumiradx, Inc., a foreign-owned, for-profit organization. The contract is for Lumiradx to provide a SARS-CoV-2 & Flu A/B high sensitivity antigen assay under the RADX Tech program. The contract has an ultimate completion date of May 31, 2022 and was awarded on September 30, 2021. This contract is not associated with any set-aside designation.
Generated 10/26/24, 9:53 AM